Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas
Open Access
- 15 September 2008
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 49 (10), 1579-1584
- https://doi.org/10.2967/jnumed.108.053694
Abstract
By allowing simultaneous measurements of tumor volume and metabolic activity, integrated PET/CT opens up new approaches for assessing tumor response to therapy. The aim of this study was to determine whether combined assessment of tumor volume and metabolic activity improves the accuracy of 18F-FDG PET for predicting histopathologic tumor response in patients with soft-tissue sarcomas. Methods: Twenty patients with locally advanced high-grade soft-tissue sarcoma (10 men and 10 women; mean age, 49 ± 17 y) were studied by 18F-FDG PET/CT before and after preoperative therapy. CT tumor volume (CTvol) was measured by delineating tumor borders on consecutive slices of the CT scan. Mean and maximum 18F-FDG standardized uptake value within this volume (SUVmean and SUVmax, respectively) were determined. Two indices of total lesion glycolysis (TLG) were calculated by multiplying tumor volume by SUVmean (TLGmean) and SUVmax (TLGmax). Changes in CTvol, SUVmean, SUVmax, TLGmean, and TLGmax after chemotherapy were correlated with histopathologic tumor response (≥95% treatment-induced tumor necrosis). Accuracy for predicting histopathologic response was compared by receiver-operating-characteristic (ROC) curve analysis. Results: Baseline SUVmax, SUVmean, CTvol, TLGmean, and TLGmax were 11.22 g/mL, 2.84 g/mL, 544.1 mL, 1,619.8 g, and 8852.9 g, respectively. After neoadjuvant therapy, all parameters except CTvol showed a significant decline (ΔSUVmax = −51%, P < 0.001; ΔSUVmean = −40%, P < 0.001; ΔCTvol = −14%, P = 0.37; ΔTLGmean = −44%, P = 0.006; and ΔTLGmax = −54%, P = 0.001). SUV changes in histopathologic responders (n = 6) were significantly more pronounced than those in nonresponders (n = 14) (P = 0.001). Histopathologic response was well predicted by changes in SUVmean and SUVmax (area under ROC curve [AUC] = 1.0 and 0.98, respectively) followed by TLGmean (AUC = 0.77) and TLGmax (AUC = 0.74). In contrast, changes in CTvol did not allow prediction of treatment response (AUC = 0.48). Conclusion: In this population of patients with sarcoma, TLG was less accurate in predicting tumor response than were measurements of the intratumoral 18F-FDG concentration (SUVmax, SUVmean). Further evaluation of TLG in larger patient populations and other tumor types is necessary to determine the value of this conceptually attractive parameter for assessing tumor response.This publication has 26 references indexed in Scilit:
- Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue SarcomasClinical Cancer Research, 2008
- Monitoring primary breast cancer throughout chemotherapy using FDG-PETBreast Cancer Research and Treatment, 2006
- Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514Journal of Clinical Oncology, 2006
- Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory ApprovalClinical Cancer Research, 2005
- Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study.2005
- Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapyCancer, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion GlycolysisClinical Positron Imaging, 1999
- Attenuation correction for a combined 3D PET/CT scannerMedical Physics, 1998
- A method of comparing the areas under receiver operating characteristic curves derived from the same cases.Radiology, 1983